Rituximab and omalizumab in severe, refractory insulin allergy

N Engl J Med. 2009 Mar 5;360(10):1045-7. doi: 10.1056/NEJMc0808282.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Allergic Agents / therapeutic use*
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Diabetes Mellitus, Type 1 / drug therapy
  • Drug Eruptions / drug therapy*
  • Drug Eruptions / etiology
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunoglobulin E / blood
  • Immunologic Factors / therapeutic use*
  • Insulin / adverse effects*
  • Middle Aged
  • Omalizumab
  • Rituximab

Substances

  • Anti-Allergic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Insulin
  • Omalizumab
  • Immunoglobulin E
  • Rituximab